Biotech RadarJobs updated

COMPANY

Ellodi Pharmaceuticals

HQ: Blue Bell, PA source · ellodipharma.com ↗

Clinical Phase 3

Keywords: eosinophilic esophagitis APT-1011

Location: Blue Bell, PA · source · Oct 15, 2026

Profile checked Oct 10, 2026

4Trials (company is sponsor)

Timeline

  1. Trial start Phase 3: 24-Week Induction Study of APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE 3) source ↗
  2. Trial start Phase 3: Efficacy and Safety APT-1011 in Adolescent Subjects With Eosinophilic Esophagitis (EoE) - A Sub-Study of the FLUTE-2 Trial source ↗
  3. Trial start Phase 3: Efficacy and Safety APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE-2) source ↗

Clinical trials (lead sponsor) 4

RecordTitlePhaseStatusStartPrimary completion
NCT05095116Expanded Access Protocol for Patients With Eosinophilic EsophagitisNot listedNo longer availableNot listedNot listed
NCT0563474624-Week Induction Study of APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE 3)Phase 3CompletedDec 29, 2022Aug 12, 2024 (actual)
NCT05083312Efficacy and Safety APT-1011 in Adolescent Subjects With Eosinophilic Esophagitis (EoE) - A Sub-Study of the FLUTE-2 TrialPhase 3CompletedSep 30, 2021Sep 5, 2022 (actual)
NCT04281108Efficacy and Safety APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE-2)Phase 3CompletedJan 30, 2020May 5, 2022 (actual)
Feedback